DG
URGN icon

Delek Group’s UroGen Pharma URGN Stock Holding History

Delek Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$14.3M Buy
408,303
+95,192
+30% +$3.51M 0.55% 67
2019
Q1 		$11.5M Buy
313,111
+149,676
+92% +$6.27M 0.48% 82
2018
Q4 		$7.23M Buy
163,435
+63,815
+64% +$2.87M 0.33% 102
2018
Q3 		$4.67M Buy
+99,620
New +$4.63M 0.2% 132

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Delek Group's URGN Position: Q2 2019 in Review

Delek Group increased its UroGen Pharma (URGN) stake by 30% in Q2 2019, buying an estimated $3.51M and bringing the position to 408,303 shares worth $14.3M. The position accounts for 0.55% of the portfolio, ranked #67.

Delek Group first reported a position in URGN in Q3 2018 and has held it in 4 quarters since. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2019.

  • Delek Group held 408,303 shares of UroGen Pharma worth $14.3M as of Q2 2019.
  • Delek Group bought 95,192 UroGen Pharma shares in Q2 2019, an estimated $3.51M.
  • UroGen Pharma made up 0.55% of Delek Group's portfolio in Q2 2019, its #67 holding.
  • Delek Group first reported a position in UroGen Pharma in Q3 2018 and has held it in 4 quarters since.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.